Bayer Issues Earnings Nov. 25; Update Expected On Strategic Realignment
This article was originally published in The Pink Sheet Daily
Company’s plans to expand its U.S. oncology business and its recent deal with Schering-Plough for primary care product marketing rights in the U.S. are likely to be a focus of discussion. Bayer’s shareholders approve spin-off of Lanxess chemicals/polymers unit.
You may also be interested in...
Bayer abandons primary care market in U.S. and will cut 1,800 sales positions. Schering-Plough will take over marketing of Avelox and Cipro as well as Bayer's portion of Levitra co-promotion efforts.
Bayer is setting up a new oncology division in West Haven, Conn. as the focus of its U.S. prescription drug business following a Sept. 13 licensing deal with Schering-Plough
Please take our brief reader survey to help us better understand your content and delivery needs.